Fig. 3From: Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of pediatric nephrotic syndrome: a pilot studyChange in TNF levels from baseline to 26 weeks while on transcutaneous vagus nerve stimulation therapyBack to article page